DOI: https://dx.doi.org/10.18203/2349-2902.isj20220962
Published: 2022-03-28

Rare case of giant extra gastrointestinal stromal tumor of wild variant

B. S. Ramesh, Pushpa S. Kumar, Hosni Mubarak Khan, Veeksha V. Shetty

Abstract


Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms of gastrointestinal tract. The interstitial cells of Cajal (pacemaker cells) act as normal counterpart of tumor. They are rare cancers with incidence of 1.5 in 100000. KIT and PDGFRA gene mutations are the most common pathogenetic causes, whereas a minority of GISTs do not harbour either of the mutations, referred to as wild type GISTs. A minority of cases are extra gastrointestinal (EGIST), arising from mesentry, omentum and retroperitoneum. We present a wild type EGIST measuring 32×24×15 cm and weighing approximately 6 kg.


Keywords


GIST, EGIST, Mesenchymal neoplasm, Wild type

Full Text:

PDF

References


Kindblom LG, Remotti HE, Aldenborg F. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259-69.

Søreide K, Sandvik OM, Søreide JA. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39-46.

Von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors. J Clin Oncol. 2018;36:136-143.

Novelli M, Rossi S, Rodriguez-Justo M, Taniere P. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology. 2010;57:259-70.

Pantaleo MA, Nannini M, Corless CL, Heinrich MC. Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. Cancer Med. 2015;4:101-3.

DeMatteo RP, Lewis JJ, Leung D, Mudan SS. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-8.

Tirumani SH, Shinagare AB, Jagannathan JP. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection. Eur J Surg Oncol. 2014;40:420-8.

Casali PG, Zalcberg J, Le Cesne A. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. J Clin Oncol. 2017;35:1713-20.

Plumb AA, Kochhar R, Leahy M, Taylor MB. Patterns of recurrence of gastrointestinal stromal tumour (GIST) following complete resection: implications for follow-up. Clin Radiol. 2013;68:770-5.